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Retinoid X receptor-α (RXRα), a unique member of the nuclear receptor (NR) superfamily, plays an important role in many biological processes ranging from apoptosis, cell differentiation, and growth to lipid metabolism.^[@ref1]−[@ref4]^ Altered expression and function of RXRα is implicated in the development of a number of diseases and cancer.^[@ref1]−[@ref4]^ Thus, RXRα has been an attractive and important target for pharmacologic interventions and therapeutic applications.^[@ref1]−[@ref4]^ The first identified natural RXRα ligand was the vitamin A derivative retinoid 9-*cis* retinoic acid (9-*cis*-RA).^[@ref1]−[@ref4]^ Some fatty acids such as docosahexaenoic acid, oleic acid, and phytanic acid also serve as ligands for RXRα. 9-*cis*-RA and synthetic ligands (rexinoids) are effective in preventing tumorigenesis and treating inflammatory diseases. Targretin (bexarotene), a rexinoid, was approved for treating human cutaneous T-cell lymphoma.^[@ref1],[@ref5]^ RXRα acts primarily as a ligand-dependent transcription factor through forming homodimer with itself or heterodimer with other members of the NR family.

Structurally, RXRα is composed of three main functional domains: an N-terminal transcriptional activation function (AF-1) region, a DNA-binding domain and a ligand-binding domain (LBD).^[@ref3],[@ref4]^ The LBD possesses a canonical ligand-binding pocket (LBP), a transactivation function domain 2 (AF-2) composed of Helix 12 of the LBD, a coregulator binding surface, and a dimerization surface.^[@ref3],[@ref4]^ The ligand-dependent transcription regulation is predominately mediated through H12 that is highly mobile. The coregulator binding surface is a region where the binding sites of corepressor and the coactivator overlap. Canonical ligands bind to the LBP to mediate directly the transcriptional activity and so identifying and optimizing molecules that bind to its classical LBP has been the focus of drug discovery efforts targeting RXRα. A large pool of RXRα ligands that bind to the LBP have been designed and reported.^[@ref1],[@ref6]^ However, there are key limitations of treatment with rexinoids including unwanted side effects such as rising of plasma triglyceride levels, suppression of the thyroid hormone axis, and induction of hepatomegaly.^[@ref1],[@ref4]−[@ref6]^ The current challenge is to discover selective RXRα modulators with the desired pharmacological activities but lacking undesired side effects.^[@ref1],[@ref4],[@ref6]^ Therefore, targeting potential binding sites other than LBP could become a new paradigm for RXRα-based drug discovery. One of these potential binding sites is the coregulator-binding site.

Compounds that bind to the coregulator-binding site have been successfully demonstrated for other NRs, including estrogen receptor (ER),^[@ref7]^ androgen receptor,^[@ref8],[@ref9]^ vitamin D receptor, and thyroid receptor.^[@ref10]−[@ref12]^ However, compounds that bind to the coregulator-binding site of RXRα have not been reported. Inspired by the successes reported for other NRs, we employed docking-based virtual screening (VS) to identify RXRα modulators targeting the coregulator-binding site. Here we report the identification and characterization of a small molecule that binds to the coregulator-binding site of RXRα to regulate its nongenomic actions.

Docking-based VS is a popular approach used in drug discovery where the structure of the target or target homologue is available.^[@ref13]^ Many crystal structures of RXRα LBD have been determined either in apo form or in complex with ligands or with both ligand and coregulator peptide,^[@ref4],[@ref6]^ offering an excellent opportunity to identify new RXRα binding compounds using docking-based VS. A chemical library of 200,000 compounds, commercially available from Specs ([www.specs.net](www.specs.net)), was subjected to a Pipeline Pilot protocol^[@ref14]^ to filter out compounds that failed the Lipinski rules^[@ref15]^ and that are potentially reactive and contain undesired groups.^[@ref16]^ About 102,000 compounds left were then docked using Glide^[@ref17]^ to the coactivator binding site on RXRα using the structure of RXRα LBD in complex with CD3254 and a coactivator peptide (PDB code 3FUG).^[@ref18]^ Fourteen compounds (Figure S1A, [Supporting Information](#notes-1){ref-type="notes"}) were selected for purchase and biological testing after visual evaluation of the first 300 compounds with the best docking score. Compound **7** (Figure [1](#fig1){ref-type="fig"}A) showed the strongest antagonist activity (Figure S1B, [Supporting Information](#notes-1){ref-type="notes"}) among these candidate compounds. Interestingly, part of **7** is similar to a recently reported androgen receptor inhibitor that is a diarylhydrazide and functions also via binding to the coactivator-binding site.^[@ref8]^ Similar to the classical RXRα antagonist BI1003,^[@ref19]^**7** inhibited 9-*cis*-RA-induced RXRα transactivation in a dose-dependent manner (Figure [1](#fig1){ref-type="fig"}A). So analogues of **7** were searched and selected for preliminary SAR studies. Nine analogues (Figure [1](#fig1){ref-type="fig"}B) were available commercially and ordered and tested for their RXRα antagonist effect and their selectivity toward other nuclear receptors including ER, retinoic acid receptor-γ (RARγ), and Nur77 (Figure [1](#fig1){ref-type="fig"}C), as well as glucocorticoid receptor (GR), PPARγ, and LXRα (Figure S2, [Supporting Information](#notes-1){ref-type="notes"}). Among these compounds, **23** (ordered from [www.specs.net](www.specs.net) under catalog number AE-848/34436002) showed an antagonist activity similar to **7**, but demonstrated the best selectivity for RXRα. It significantly inhibited the activity of RXRα, but not ER, GR, and Nur77, and showed slight inhibition of transactivation of RARα, RARγ, PPARγ, and LXRα (Figures [1](#fig1){ref-type="fig"}C and S2, [Supporting Information](#notes-1){ref-type="notes"}), which are known to heterodimerize with RXRα.^[@ref20]^ Further, compound **23** showed very little inhibitory effect on transactivation of RXRα/RARα and RXRα/LXRα heterodimers (Figure S3, [Supporting Information](#notes-1){ref-type="notes"}). We also tested the antagonist effect of **23** toward the RXR subtypes RXRγ and RXRβ. The results showed that overall **23** is more selective toward RXRα though it demonstrated some inhibition of transactivation of RXRγ and RXRβ (Figure S4, [Supporting Information](#notes-1){ref-type="notes"}). Thus, **23** is a new RXRα-selective antagonist.

![Identification of RXRα-selective antagonist **23**. (A) Compound **7** and its antagonist effect on RXRα transactivation. MCF-7 cells cotransfected with the reporter plasmids pG5-Luc and pBind-RXRα-LBD were treated with 9-*cis*-RA (10^--7^ M) alone or together with **7** or BI1003 for 18 h. Luciferase reporter activities were measured by using the Dual-Luciferase Reporter Assay System. Transfection efficiency was normalized to Renilla luciferase activity. (B) Compounds related to **7** identified by computational approach. (C) Antagonist effect of compound **7** and analogues. MCF-7 cells cotransfected with pG5-Luc and pBind-RXRα-LBD, pBind-ER-LBD, pBind-RARγ-LBD, or pBind-Nur77-LBD were treated, respectively, with 9-*cis*-RA (10^--7^ M), propyl pyrazole triol (PPT) (10 μM), and all-*trans*-RA (10^--7^ M), in the presence or absence of compound (10 μM) for 18 h. Reporter activities were measured as described above. Data shown are mean ± SD.](ml-2014-000405_0001){#fig1}

A dose-dependent study showed that **23** could inhibit 9-c*is*-RA-induced RXRα transactivation with an IC~50~ of 2.45 μM (Figure [2](#fig2){ref-type="fig"}A). By using Biacore's Surface plasmon resonance (SPR) technology, we found that **23** could bind to RXRα with a *K*~d~ of 4.88 × 10^--7^ M (Figure [2](#fig2){ref-type="fig"}B). The binding of **23** to RXRα is unlikely due to its binding to the RXRα LBP, as it failed to compete with the binding of \[^3^H\]9-*cis*-RA to the RXRα LBP. By contrast, 9-*cis*-RA competed well with \[^3^H\]9-*cis*-RA for binding to RXRα (Figure [2](#fig2){ref-type="fig"}C).

![RXRα antagonist **23** binds RXRα at a site other than LBP. (A) Dose-dependent effect of **23** on inhibiting RXRα transactivation. HEK293T cells cotransfected with pG5-Luc and pBind-RXRα-LBD were treated with 9-*cis*-RA (10^---7^ M) alone or together with the indicated concentration of **23** for 18 h. (B) SPR assay. Gradient concentrations of **23** were injected through flow cells immobilized with RXRα-LBD. The kinetic profiles are shown. The dissociation constant (*K*~d~) of the **23**/RXRα-LBD complex was calculated to be 4.881 × 10^--7^ M. (C) Compound **23** fails to compete with 9-*cis*-RA for binding to RXRα LBP. The bacterially expressed His-tagged RXRα-LBD was incubated with 7.5 nM \[^3^H\]-9-*cis*-RA in the presence or absence of the indicated concentrations of 9-*cis*-RA or **23**. The RXRα LBD was captured by nickel-coated beads. Bound \[^3^H\]-9-*cis*-RA was quantitated by liquid scintillation counting. Data shown are mean ± SD.](ml-2014-000405_0002){#fig2}

To confirm that **23** binds to the coregulator-binding site on the surface of RXRα, mutagenesis in the site was carried out to validate its importance in the antagonist effect of **23**. Mutations in the coactivator-binding site might impact not only the binding of **23** but also the binding of coactivator, which would preclude our evaluation by the reporter assay that depends on the binding of the coactivator. However, comparison of the interactions of **23** and coactivator to RXRα identified that Val298 in the Helix 4 of RXRα is critical for the binding of **23** but not the coactivator (Figure [3](#fig3){ref-type="fig"}A). Thus, Val298 was mutated to Ser, and the resulting mutant, RXRα-V298S, was subjected to evaluation by the reporter assay. 9-*cis*-RA was able to activate RXRα-V298S, similar to its effect on RXRα (Figures [3](#fig3){ref-type="fig"}B and S5, [Supporting Information](#notes-1){ref-type="notes"}), suggesting that mutation of Val298 did not impair the ability of RXRα to bind to 9-*cis*-RA and to recruit the coactivator. Classical antagonists, such as BI1003^[@ref19]^ and UVI3003,^[@ref21]^ also potently inhibited the 9-*cis*-RA-induced RXRα-V298S activity. By contrast, the antagonist effect of **23** was largely reduced as compared to its inhibitory effect on RXRα. Thus, Val298 is crucial for the binding of 23 but not classical RXRα ligands and coregulators.

![Coregulator-binding site of RXRα but not its LBP is critical for the antagonist effect of **23**. (A) Val298 is critical for **23** binding revealed by modeling. (B) Mutation of Val298 impairs the antagonist effect of **23**. HEK-293T cells cotransfected with pG5-Luc and pBind-RXRα/V298S were treated with the indicated compounds for 18 h. (C) Substitution of Cys432 and Ala272 in RXRα with Trp impairs 9-*cis*-RA binding. Lysates of HEK-293T cells transfected with RXRα, RXRα-C432W, or RXRα/A272W were incubated with 7.5 nM \[^3^H\]-9-*cis*-RA in the presence or absence of unlabeled 9-*cis*-RA. The Myc-RXRα was captured by hydroxylapatite. Bound \[^3^H\]-9-*cis*-RA was quantitated. (D,E) Transactivation of RXRα LBP mutants. HEK-293T cells cotransfected with pG5-Luc and the indicated RXRα or mutant expression vector were treated with 9-*cis*-RA (10^--7^ M), BI1003 (1 μM), or the indicated concentration of **23** for 18 h. Data shown are mean ± SD.](ml-2014-000405_0003){#fig3}

To further exclude the possibility that **23** binds to the LBP of RXRα, we designed and constructed RXRα mutants with its LBP blocked. Computational modeling suggested that substitution of Cys432 and Ala272 in the LBP with a bulky amino acid such as Trp could block the passage of a ligand to the LBP. Indeed, RXRα/C432W and RXRα/A272W failed to show any binding to \[^3^H\]-9-*cis*-RA (Figure [3](#fig3){ref-type="fig"}C), even though the mutant proteins were well expressed (Figure S6, [Supporting Information](#notes-1){ref-type="notes"}). In contrast, RXRα bound well to \[^3^H\]-9-*cis*-RA, which was competed away by unlabeled 9-*cis*-RA. F313A mutation is known to shift RXRα from an apo-receptor to a constitutively active form.^[@ref22]^ In order to utilize LBP-blocked mutants to evaluate the antagonist effect of **23**, Phe313 in RXRα/C432W and RXRα/A272W was substituted with Ala. As reported,^[@ref22]^ RXRα-F313A is constitutived as active in the absence of 9-*cis*-RA. Similar to RXRα-F313A, both RXRα-C432W/F313A and RXRα-A272W/F313A mutants showed strong constitutive transcriptional activity (Figure [3](#fig3){ref-type="fig"}D), making them ideal mutants to evaluate the LBP-independent antagonist effect of **23**. Treatment of cells with **23** could effectively inhibit their constitutive activity in a dose-dependent manner, similar to its effect on RXRα (Figure [3](#fig3){ref-type="fig"}E). By contrast, BI1003, which showed potent inhibitory effect on the transactivation of RXRα and RXRα-F313A by binding to their LBP, had much reduced inhibitory effect on the constitutive transactivation of both mutants. Thus, the blockage of the LBP of RXRα, which affects the activity of 9-*cis*-RA and the classical RXRα antagonist BI1003, has no effect on the antagonist activity of **23**, further confirming unique RXRα binding activity of **23**.

We recently reported that modulation of RXRα activity by certain RXRα ligands, such as Sulindac and analogues, could inhibit AKT activation in cancer cells.^[@ref23],[@ref24]^ We therefore asked whether the LBP-independent binding of **23** could suppress AKT activation. A549 lung cancer and HepG2 liver cancer cells were treated with **23**, and the activation of AKT was examined. As shown in Figure [4](#fig4){ref-type="fig"}A, AKT activation in these cells was inhibited by **23** dose-dependently, with apparent inhibition observed when 5--10 μM of **23** was used. Since TNFα could induce RXRα-dependent AKT activation,^[@ref24]^ cells were also treated with TNFα, and its activation of AKT in the absence or presence of **23** was examined. Treatment of cells with TNFα enhanced AKT activation, which was also suppressed by **23** (Figure [4](#fig4){ref-type="fig"}A). Similar results were obtained in PC-3 prostate cancer cells (Figure S7, [Supporting Information](#notes-1){ref-type="notes"}) and other cancer cells including colon cancer and pancreatic cancer cells (data not shown). We also evaluated the apoptotic effect of **23** in cancer cells. A549 and HepG2 cells were treated with **23** in the absence or presence of TNFα, and the cleavage of PARP, an indication of apoptosis in cancer cells, was examined by immunoblotting (Figure [4](#fig4){ref-type="fig"}B). Treatment of cancer cells with **23** induced PARP cleavage, which was further enhanced by TNFα treatment. Such apoptosis induction by **23** correlated well with its inhibition of AKT activation, suggesting that AKT inhibition might play a role in its induction of apoptosis.

![Biological evaluation of **23**. (A,B) Inhibition of AKT activation (A) and induction of apoptosis (B). Cells were pretreated with **23** for 24 h before being exposed to TNFα (20 ng/mL) for an additional 30 min. Lysates prepared were analyzed by Western blotting for AKT activation (A) or PARP cleavage (B). (C) RXRα-dependent effects of **23**. A549 cells transfected with RXRα siRNA or control siRNA for 48 h were treated with **23** for 24 h before being exposed to TNFα (20 ng/mL) for an additional 30 min. Lysates prepared were analyzed by Western blotting. (D) Inhibition of p85α interaction with tRXRα by **23**. A549 cells transfected with myc-RXRα-Δ80 expression vector were analyzed for their interaction with endogenous p85α by coimmunoprecipitation assay using anti-Myc antibody. Immunoprecipitates were analyzed by Western blotting for the presence of p85α and Myc-RXRα-Δ80. One of three to five similar experiments is shown.](ml-2014-000405_0004){#fig4}

To determine whether the expression of RXRα plays a role in the inhibition of AKT activation and the induction of apoptosis by **23**, A549 cells were transfected with RXRα siRNA and evaluated for its effect on the role of **23** in AKT activation and apoptosis induction. Transfection of RXRα siRNA reduced the levels of RXRα and its truncated version, tRXRα,^[@ref24]^ and diminished the effect of **23** on inducing PARP cleavage and inhibiting AKT activation (Figure [4](#fig4){ref-type="fig"}C). Furthermore, the inhibitory effect of compound **23** on the growth of cancer cells can be significantly enhanced by RXRα (Figure S8, [Supporting Information](#notes-1){ref-type="notes"}). These results demonstrate that RXRα plays a crucial role in mediating the biological effect of **23** on cell death.

We next determined whether **23** could affect tRXRα interaction with the p85α regulatory subunit of PI3K, an event known to activate PI3K/AKT.^[@ref24]^ A549 cells were transfected with Myc-tagged RXRα-Δ80, a mutant that mimics tRXRα,^[@ref24]^ and treated with or without TNFα and/or **23**. Co-immunoprecipitation assays using anti-Myc antibody showed that p85α was coimmunoprecipitated together with Myc-RXRα-Δ80 in cells treated with TNFα (Figure [4](#fig4){ref-type="fig"}D), demonstrating their interaction. However, when cells were cotreated with **23**, TNFα-induced interaction of Myc-RXRα-Δ80 with p85α was almost completely inhibited. Thus, **23** might induce apoptosis by suppressing AKT activation through its inhibition of tRXRα interaction with p85α.

We report here through virtual screening our identification of a unique RXRα antagonist, **23**, which modulates RXRα activities through LBP-independent binding. Several lines of evidence showed that **23** acts through its binding to the surface of RXRα. First, despite its high affinity for binding to RXRα revealed by SPR study, **23** failed to compete with 9-*cis*-RA for binding to the LBP of RXRα revealed by the classical ligand competition assay (Figure [2](#fig2){ref-type="fig"}C). Second, mutation of Val298, a critical amino acid residue in the hydrophobic groove on the surface of RXRα, impaired the antagonist effect of **23** (Figure [3](#fig3){ref-type="fig"}A). Third, **23** could effectively inhibit the transcriptional activity of RXRα mutants with impaired LBP (Figure [3](#fig3){ref-type="fig"}D). To our knowledge, compounds that bind to the surface site of RXRα have not been reported. Thus, **23** represents the first small molecule capable of functionally binding to the surface site of RXRα with submicromoloar affinity.

Recent studies demonstrated that RXRα could crosstalk extensively with signal transduction pathways through its interaction with various signaling proteins,^[@ref24]^ which are likely mediated through its surface binding sites. When the effect of **23** on the PI3K/AKT signaling was examined, we found that it could suppress basal and TNFα-induced AKT activation (Figure [4](#fig4){ref-type="fig"}A) and induce apoptosis (Figure [4](#fig4){ref-type="fig"}B) in cancer cells in a RXRα-dependent manner (Figure [4](#fig4){ref-type="fig"}C). Our coimmunoprecipitation assays demonstrated that **23** could block tRXRα interaction with p85α (Figure [4](#fig4){ref-type="fig"}D). Thus, the unique surface binding of **23** could interfere with the binding of some RXRα-interacting proteins, providing an opportunity to regulate RXRα activities by targeting the coregulator-binding sites. The report of the structure of estrogen receptor-β with a second molecule of 4-hydroxytamoxifen bound in its coactivator-binding surface provides insight into the possible pharmacological effects of the drug through its binding to the surface site on NR.^[@ref25]^ Thus, our demonstrations that **23** could bind to the coregulator-binding site of RXRα and regulate the PI3K/AKT signaling pathway and apoptosis in cancer cells provide a new approach to target a functionally important surface site on RXRα that could represent a new strategy to tackle the specificity issue.

Supplemental Figures 1 to 8 and detailed experimental procedures. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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